Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)
Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –
Protalix BioTherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Protalix BioTherapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.34M, up 23.7% year over year. For fiscal 2025 it was $19.57M, up 50.9% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $44.62M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.57M | +50.9% |
| FY2024 | Dec 31, 2024 | $12.97M | -24.1% |
| FY2023 | Dec 31, 2023 | $17.09M | -41.8% |
| FY2022 | Dec 31, 2022 | $29.35M | -1.3% |
| FY2021 | Dec 31, 2021 | $29.73M | -22.1% |
| FY2020 | Dec 31, 2020 | $38.17M | -14.5% |
| FY2019 | Dec 31, 2019 | $44.62M | +33.9% |
| FY2018 | Dec 31, 2018 | $33.33M | +3.6% |
| FY2017 | Dec 31, 2017 | $32.17M | +5.8% |
| FY2016 | Dec 31, 2016 | $30.41M | +22.2% |
| FY2015 | Dec 31, 2015 | $24.89M | -9.0% |
| FY2014 | Dec 31, 2014 | $27.35M | -6.4% |
| FY2013 | Dec 31, 2013 | $29.23M | -20.3% |
| FY2012 | Dec 31, 2012 | $36.67M | -3.0% |
| FY2011 | Dec 31, 2011 | $37.82M | +0.3% |
| FY2010 | Dec 31, 2010 | $37.69M | +37.6% |
| FY2009 | Dec 31, 2009 | $27.39M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.92M | +55.0% |
| Q2 FY2026 | Jun 30, 2026 | $4.35M | -27.4% |
| Q1 FY2026 | Mar 31, 2026 | $5.43M | +56.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.64M | +36.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.47M | +49.0% |
| Q2 FY2025 | Jun 30, 2025 | $5.99M | +102.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.48M | +20.4% |
| Q4 FY2024 | Dec 31, 2024 | $4.12M | +32.9% |
| Q3 FY2024 | Sep 30, 2024 | $3.00M | -18.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.96M | -33.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.89M | -50.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.10M | -44.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.67M | -50.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.48M | -41.0% |
| Q1 FY2023 | Mar 31, 2023 | $5.85M | -33.3% |
| Q4 FY2022 | Dec 31, 2022 | $5.62M | -26.5% |
| Q3 FY2022 | Sep 30, 2022 | $7.39M | +1.4% |
| Q2 FY2022 | Jun 30, 2022 | $7.58M | -1.4% |
| Q1 FY2022 | Mar 31, 2022 | $8.77M | +23.1% |
| Q4 FY2021 | Dec 31, 2021 | $7.64M | -30.2% |
| Q3 FY2021 | Sep 30, 2021 | $7.28M | -29.6% |
| Q2 FY2021 | Jun 30, 2021 | $7.69M | -19.9% |
| Q1 FY2021 | Mar 31, 2021 | $7.12M | -28.8% |
| Q4 FY2020 | Dec 31, 2020 | $10.95M | -17.8% |
| Q1 FY2020 | Mar 31, 2020 | $10.34M | -11.6% |
| Q4 FY2019 | Dec 31, 2019 | $9.60M | +0.2% |
| Q3 FY2019 | Sep 30, 2019 | $10.00M | -0.7% |
| Q2 FY2019 | Jun 30, 2019 | $13.32M | +78.2% |
| Q1 FY2019 | Mar 31, 2019 | $11.70M | +60.6% |
| Q4 FY2018 | Dec 31, 2018 | $9.58M | -2.1% |
| Q3 FY2018 | Sep 30, 2018 | $10.07M | +41.5% |
| Q2 FY2018 | Jun 30, 2018 | $7.48M | -19.6% |
| Q1 FY2018 | Mar 31, 2018 | $7.29M | +22.1% |
| Q4 FY2017 | Dec 31, 2017 | $9.78M | +45.7% |
| Q3 FY2017 | Sep 30, 2017 | $7.12M | +12.0% |
| Q2 FY2017 | Jun 30, 2017 | $9.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.71M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.35M | – |
See a number that looks wrong?